Find participating medical centers and current study status in each of them

    Find participating medical centers

    What happens to a medicine (pralsetinib) when given to people with unhealthy livers

    A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Pralsetinib in Subjects With Moderate or Severe Hepatic Impairment Compared to Healthy Subjects

    • Metabolic Disorder
    • Hepatic Insufficiency
    • Liver Failure